<p>Jennison Associates LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第三季度将其在 NewAmsterdam Pharma Company N.V.（NASDAQ:NAMS - 免费报告）的持股增加了 42.5%。该公司在本季度额外购买了 1,252,451 股后，持有该公司 4,198,554 股股票。到最近一个季度末，Jennison Associates LLC 持有的 NewAmsterdam Pharma 股票约占 3.73%，价值 119,407,000 美元。</p>
<p>其他一些机构投资者和对冲基金最近也买卖了该股票的股份。Adage Capital Partners GP L.L.C. 在第二季度将其在 NewAmsterdam Pharma 的持股增加了 54.5%。Adage Capital Partners GP L.L.C. 目前持有该公司 3,013,009 股股票，价值 54,566,000 美元，此前在上个季度购买了 1,062,359 股。Maverick Capital Ltd. 在第二季度将其在 NewAmsterdam Pharma 的持股增加了 178.8%。Maverick Capital Ltd. 目前持有该公司 1,531,874 股股票，价值 27,742,000 美元，此前在上个季度购买了 982,405 股。Frazier Life Sciences Management L.P. 在第二季度将其在 NewAmsterdam Pharma 的持股增加了 3.0%。Frazier Life Sciences Management L.P. 目前持有该公司 16,607,074 股股票，价值 300,754,000 美元，此前在上个季度购买了 490,656 股。摩根大通在第二季度将其在 NewAmsterdam Pharma 的持股增加了 47.2%。摩根大通目前持有该公司 1,458,897 股股票，价值 26,421,000 美元，此前在上个季度购买了 467,579 股。最后，Aberdeen Group plc 在第二季度将其在 NewAmsterdam Pharma 的持股增加了 95.0%。Aberdeen Group plc 目前持有该公司 735,032 股股票，价值 13,311,000 美元，此前在上个季度购买了 358,169 股。对冲基金和其他机构投资者持有该公司 89.89% 的股票。</p>
<p>获取 <strong>NewAmsterdam Pharma</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>NAMS 最近成为多份分析师报告的主题。花旗集团在 10 月 17 日的研究报告中将 NewAmsterdam Pharma 的目标价格从 42.00 美元上调至 50.00 美元，并给予该公司 &#34;买入&#34; 评级。加拿大皇家银行在周三将 NewAmsterdam Pharma 股票的目标价格从 44.00 美元上调至 47.00 美元，并给予该股票 &#34;跑赢大盘&#34; 评级。Stifel Nicolaus 在 12 月 16 日的研究报告中将 NewAmsterdam Pharma 股票的目标价格从 44.00 美元上调至 50.00 美元，并给予该公司 &#34;买入&#34; 评级。HC Wainwright 在 10 月 20 日的研究报告中开始覆盖 NewAmsterdam Pharma 股票。他们给予该公司 &#34;买入&#34; 评级和 52.00 美元的目标价格。最后，Weiss Ratings 在周四的研究报告中重申了对 NewAmsterdam Pharma 股票的 &#34;卖出（d-）&#34; 评级。九位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，NewAmsterdam Pharma 的共识评级为 &#34;适度买入&#34;，共识目标价格为 47.00 美元。</p>
<p><strong>获取我们关于 NAMS 的最新报告</strong></p>
<h2>NewAmsterdam Pharma 的内部活动</h2>
<p>在相关消息中，内部人士 Johannes Jacob Piete Kastelein 于 1 月 5 日星期一出售了 6,000 股该公司的股票。股票以平均价格 33.25 美元出售，总价值为 199,500.00 美元。出售完成后，内部人士在公司中持有 73,481 股，价值约 2,443,243.25 美元。这代表其持股减少了 7.55%。该交易在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席会计官 Louise Frederika Kooij 于 12 月 23 日星期二出售了 75,117 股该公司的股票。股票以平均价格 36.21 美元出售，总价值为 2,719,986.57 美元。出售完成后，首席会计官直接持有 15,000 股该公司的股票，价值约 543,150 美元。该交易代表其持股减少了 83.35%。该交易的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共出售了 153,647 股公司股票，价值 5,484,253 美元。当前 20.84% 的股票由内部人士持有。</p>
<h2>NewAmsterdam Pharma 的价格表现</h2>
<p>NewAmsterdam Pharma 股票在周五开盘价为 33.32 美元。NewAmsterdam Pharma Company N.V. 的 12 个月最低价为 14.06 美元，最高价为 42.00 美元。该股票的市值为 37.8 亿美元，市盈率为 -16.25，贝塔值为 0.07。该公司有 50 天简单移动平均线为 35.71 美元，200 天简单移动平均线为 30.95 美元。</p>
<p>NewAmsterdam Pharma（NASDAQ:NAMS - 获取免费报告）最后一次公布财报是在 11 月 5 日星期三。该公司报告本季度每股收益为（0.41）美元，低于市场共识预期的（0.38）美元，差额为（0.03）美元。该公司本季度的收入为 35 万美元，而分析师预期为 454 万美元。NewAmsterdam Pharma 的净利润率为 -627.59%，股本回报率为 -28.30%。分析师平均预测 NewAmsterdam Pharma Company N.V. 在当前财年将发布 -1.75 的每股收益。</p>
<h2>关于 NewAmsterdam Pharma</h2>
<p>（免费报告）</p>
<p>NewAmsterdam Pharma, Inc 是一家临床阶段的生物制药公司，专注于发现和开发用于心血管代谢疾病的新型小分子疗法。该公司的研究工作旨在通过调节参与葡萄糖调节、能量稳态和脂质代谢的途径，解决代谢综合症、肥胖和 2 型糖尿病等关键未满足的需求。</p>
<p>该公司的研发管线包含多个在不同阶段进行临床前和临床评估的小分子候选药物。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比 NewAmsterdam Pharma 更好的股票</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>没有人告诉你的 $100 万亿 AI 故事</li>
<li>特朗普的 AI 秘密：比 Nvidia 快 100 倍</li>
<li>周一上午 9:30 买入这只股票！</li>
<li>一项价值数万亿的美国 “出生权” 主张 - 静悄悄地激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkFNUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkFNUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 NewAmsterdam Pharma 吗？</h2>
<p>在考虑投资 NewAmsterdam Pharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，而 NewAmsterdam Pharma 并不在名单上。</p>
<p>虽然 NewAmsterdam Pharma 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NAMS

<p>Jennison Associates LLC 在第三季度将其在 NewAmsterdam Pharma Company N.V. 的持股增加了 42.5%，目前持有 4,198,554 股，价值 1.194 亿美元。其他机构投资者也增加了他们的持仓。分析师对该股票给予了 “适度买入” 的共识评级，目标价格为 47.00 美元。近期有内部人士出售股票的报告，内部人士持有该股票的 20.84%。NewAmsterdam Pharma 的股票开盘价为 33.32 美元，12 个月的价格区间为 14.06 美元至 42.00 美元</p>

<p>Jennison Associates LLC raised its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 42.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,198,554 shares of the company's stock after buying an additional 1,252,451 shares during the quarter. Jennison Associates LLC owned approximately 3.73% of NewAmsterdam Pharma worth $119,407,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Jennison Associates LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第三季度将其在 NewAmsterdam Pharma Company N.V.（NASDAQ:NAMS - 免费报告）的持股增加了 42.5%。该公司在本季度额外购买了 1,252,451 股后，持有该公司 4,198,554 股股票。到最近一个季度末，Jennison Associates LLC 持有的 NewAmsterdam Pharma 股票约占 3.73%，价值 119,407,000 美元。</p>
</div><p>A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. lifted its position in shares of NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company's stock worth $54,566,000 after purchasing an additional 1,062,359 shares in the last quarter. Maverick Capital Ltd. boosted its position in NewAmsterdam Pharma by 178.8% in the 2nd quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company's stock valued at $27,742,000 after buying an additional 982,405 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in NewAmsterdam Pharma by 3.0% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company's stock valued at $300,754,000 after buying an additional 490,656 shares during the last quarter. JPMorgan Chase &amp; Co. grew its stake in shares of NewAmsterdam Pharma by 47.2% during the second quarter. JPMorgan Chase &amp; Co. now owns 1,458,897 shares of the company's stock valued at $26,421,000 after acquiring an additional 467,579 shares in the last quarter. Finally, Aberdeen Group plc increased its position in shares of NewAmsterdam Pharma by 95.0% during the second quarter. Aberdeen Group plc now owns 735,032 shares of the company's stock worth $13,311,000 after acquiring an additional 358,169 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也买卖了该股票的股份。Adage Capital Partners GP L.L.C. 在第二季度将其在 NewAmsterdam Pharma 的持股增加了 54.5%。Adage Capital Partners GP L.L.C. 目前持有该公司 3,013,009 股股票，价值 54,566,000 美元，此前在上个季度购买了 1,062,359 股。Maverick Capital Ltd. 在第二季度将其在 NewAmsterdam Pharma 的持股增加了 178.8%。Maverick Capital Ltd. 目前持有该公司 1,531,874 股股票，价值 27,742,000 美元，此前在上个季度购买了 982,405 股。Frazier Life Sciences Management L.P. 在第二季度将其在 NewAmsterdam Pharma 的持股增加了 3.0%。Frazier Life Sciences Management L.P. 目前持有该公司 16,607,074 股股票，价值 300,754,000 美元，此前在上个季度购买了 490,656 股。摩根大通在第二季度将其在 NewAmsterdam Pharma 的持股增加了 47.2%。摩根大通目前持有该公司 1,458,897 股股票，价值 26,421,000 美元，此前在上个季度购买了 467,579 股。最后，Aberdeen Group plc 在第二季度将其在 NewAmsterdam Pharma 的持股增加了 95.0%。Aberdeen Group plc 目前持有该公司 735,032 股股票，价值 13,311,000 美元，此前在上个季度购买了 358,169 股。对冲基金和其他机构投资者持有该公司 89.89% 的股票。</p>
</div><p>Get <strong>NewAmsterdam Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>NewAmsterdam Pharma</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>NAMS has been the topic of a number of recent analyst reports. Citigroup upped their target price on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, October 17th. Royal Bank Of Canada lifted their price target on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an &#34;outperform&#34; rating in a research note on Wednesday. Stifel Nicolaus increased their price objective on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, December 16th. HC Wainwright initiated coverage on shares of NewAmsterdam Pharma in a research report on Monday, October 20th. They issued a &#34;buy&#34; rating and a $52.00 target price for the company. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of NewAmsterdam Pharma in a research note on Thursday. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, NewAmsterdam Pharma has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $47.00.</p>
<div class="lb-trans"><p>NAMS 最近成为多份分析师报告的主题。花旗集团在 10 月 17 日的研究报告中将 NewAmsterdam Pharma 的目标价格从 42.00 美元上调至 50.00 美元，并给予该公司 &#34;买入&#34; 评级。加拿大皇家银行在周三将 NewAmsterdam Pharma 股票的目标价格从 44.00 美元上调至 47.00 美元，并给予该股票 &#34;跑赢大盘&#34; 评级。Stifel Nicolaus 在 12 月 16 日的研究报告中将 NewAmsterdam Pharma 股票的目标价格从 44.00 美元上调至 50.00 美元，并给予该公司 &#34;买入&#34; 评级。HC Wainwright 在 10 月 20 日的研究报告中开始覆盖 NewAmsterdam Pharma 股票。他们给予该公司 &#34;买入&#34; 评级和 52.00 美元的目标价格。最后，Weiss Ratings 在周四的研究报告中重申了对 NewAmsterdam Pharma 股票的 &#34;卖出（d-）&#34; 评级。九位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，NewAmsterdam Pharma 的共识评级为 &#34;适度买入&#34;，共识目标价格为 47.00 美元。</p>
</div><p><strong>Get Our Latest Report on NAMS</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 NAMS 的最新报告</strong></p>
</div><h2>Insider Activity at NewAmsterdam Pharma</h2>
<div class="lb-trans"><h2>NewAmsterdam Pharma 的内部活动</h2>
</div><p>In related news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the company's stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the completion of the sale, the insider owned 73,481 shares in the company, valued at approximately $2,443,243.25. This represents a 7.55% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CAO Louise Frederika Kooij sold 75,117 shares of the firm's stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57. Following the completion of the sale, the chief accounting officer directly owned 15,000 shares of the company's stock, valued at approximately $543,150. This trade represents a 83.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 153,647 shares of company stock worth $5,484,253. 20.84% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Johannes Jacob Piete Kastelein 于 1 月 5 日星期一出售了 6,000 股该公司的股票。股票以平均价格 33.25 美元出售，总价值为 199,500.00 美元。出售完成后，内部人士在公司中持有 73,481 股，价值约 2,443,243.25 美元。这代表其持股减少了 7.55%。该交易在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席会计官 Louise Frederika Kooij 于 12 月 23 日星期二出售了 75,117 股该公司的股票。股票以平均价格 36.21 美元出售，总价值为 2,719,986.57 美元。出售完成后，首席会计官直接持有 15,000 股该公司的股票，价值约 543,150 美元。该交易代表其持股减少了 83.35%。该交易的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共出售了 153,647 股公司股票，价值 5,484,253 美元。当前 20.84% 的股票由内部人士持有。</p>
</div><h2>NewAmsterdam Pharma Price Performance</h2>
<div class="lb-trans"><h2>NewAmsterdam Pharma 的价格表现</h2>
</div><p>NewAmsterdam Pharma stock opened at $33.32 on Friday. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $42.00. The stock has a market capitalization of $3.78 billion, a PE ratio of -16.25 and a beta of 0.07. The firm has a 50 day simple moving average of $35.71 and a 200-day simple moving average of $30.95.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma 股票在周五开盘价为 33.32 美元。NewAmsterdam Pharma Company N.V. 的 12 个月最低价为 14.06 美元，最高价为 42.00 美元。该股票的市值为 37.8 亿美元，市盈率为 -16.25，贝塔值为 0.07。该公司有 50 天简单移动平均线为 35.71 美元，200 天简单移动平均线为 30.95 美元。</p>
</div><p>NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The company had revenue of $0.35 million for the quarter, compared to analysts' expectations of $4.54 million. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. On average, analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma（NASDAQ:NAMS - 获取免费报告）最后一次公布财报是在 11 月 5 日星期三。该公司报告本季度每股收益为（0.41）美元，低于市场共识预期的（0.38）美元，差额为（0.03）美元。该公司本季度的收入为 35 万美元，而分析师预期为 454 万美元。NewAmsterdam Pharma 的净利润率为 -627.59%，股本回报率为 -28.30%。分析师平均预测 NewAmsterdam Pharma Company N.V. 在当前财年将发布 -1.75 的每股收益。</p>
</div><h2>About NewAmsterdam Pharma</h2>
<div class="lb-trans"><h2>关于 NewAmsterdam Pharma</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma, Inc 是一家临床阶段的生物制药公司，专注于发现和开发用于心血管代谢疾病的新型小分子疗法。该公司的研究工作旨在通过调节参与葡萄糖调节、能量稳态和脂质代谢的途径，解决代谢综合症、肥胖和 2 型糖尿病等关键未满足的需求。</p>
</div><p>The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.</p>
<div class="lb-trans"><p>该公司的研发管线包含多个在不同阶段进行临床前和临床评估的小分子候选药物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than NewAmsterdam Pharma</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
<li>Buy This Stock at 9:30 AM on MONDAY!</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 NewAmsterdam Pharma 更好的股票</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>没有人告诉你的 $100 万亿 AI 故事</li>
<li>特朗普的 AI 秘密：比 Nvidia 快 100 倍</li>
<li>周一上午 9:30 买入这只股票！</li>
<li>一项价值数万亿的美国 “出生权” 主张 - 静悄悄地激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkFNUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=NAMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in NewAmsterdam Pharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 NewAmsterdam Pharma 吗？</h2>
</div><p>Before you consider NewAmsterdam Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 NewAmsterdam Pharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，而 NewAmsterdam Pharma 并不在名单上。</p>
</div><p>While NewAmsterdam Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 NewAmsterdam Pharma 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

NewAmsterdam Pharma Company N.V. $NAMS 的股份被 Jennison Associates LLC 收购